Abstract |
This study examines the practicality and efficacy of dihydroergotamine mesylate (DHE) when self-administered subcutaneously in a population of refractory headache patients. Forty-three patients with chronic daily headache or migraine headache without aura, who had been taught self-injection of DHE either through the Raskin Protocol or in an outpatient headache clinic, were contacted by telephone and administered a questionnaire regarding usage and results from DHE injection. Ninety-two percent of patients could successfully administer DHE. Forty-six percent of patients experienced 90% or greater relief of pain and the majority of patients (77%) had greater than 50% relief. Emergency room use was decreased in 83% and 80% preferred DHE to their previous therapy. While side effects were common (79%), only four patients (9%) stopped DHE for this reason. No convincing evidence for the development of rebound headaches due to DHE was found in this sample.
|
Authors | J A Klapper, J Stanton |
Journal | Headache
(Headache)
Vol. 32
Issue 1
Pg. 21-3
(Jan 1992)
ISSN: 0017-8748 [Print] United States |
PMID | 1372884
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Dihydroergotamine
(administration & dosage, adverse effects, therapeutic use)
- Female
- Headache
(drug therapy, physiopathology)
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Palliative Care
- Recurrence
|